Home/Pipeline/Fragile X Syndrome Test

Fragile X Syndrome Test

Fragile X Syndrome

ClinicalActive

Key Facts

Indication

Fragile X Syndrome

Phase

Clinical

Status

Active

Company

Taiwan’s leading full‑service genomics and CDMO provider delivering sequencing, synthesis, and clinical testing solutions.

Drug	Company	Phase	Status
KER-0193	Kaerus Bioscience	Preclinical	Active
p70 S6 Kinase Inhibitor	Epigen Biosciences	Preclinical	Active
HLX-0206	Healx	AI Discovery	Active
ENT-3379	Enthorin Therapeutics	Phase 1	Active
AUT00206	Autifony Therapeutics	Clinical	Active
Fragile X Program	Sentinel Oncology	Preclinical	Active
Fragile X Syndrome Program	Purposeful	Discovery/Pre-clinical	Active
Fragile X Syndrome Trial	Science 37	Phase 3	Completed/Highlighted
DAYBUE® (trofinetide)	Neuren Pharmaceuticals	Phase 2	Completed
Xanamem (emestedastat)	Actinogen Medical	Phase 2	Active